initiation factor eIF4E that occurs in plant cells in two isoforms, one being the 27 preferable target of a given VPg, the remaining one still acting in host protein 28 synthesis. In animal cells only one form of eIF4E is directly involved in protein 29 synthesis. The human eIF4E is known to be an oncogene; elevated expression of 30 eIF4E leads to oncogenic transformation, cancers in animal models and poor 31 prognosis in human cancers, while reduction of the eIF4E level can reverse the 32 transformed phenotype. We show that VPg protein delivery to cells containing only 33 one eIF4E isoform involved in protein synthesis resulted in immobilization of eIF4E 34 in the cytoplasm. The region of VPg involved in the interaction with eIF4E has been 35 partially identified. Peptides derived from this region interacted better with eIF4E than 36 complete VPg protein. Here we characterized one of VPg peptides, VPg5 and we 37
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Introduction 41
Potyvirus VPg is a multifunctional protein implicated in translation, long-distance 42 movement, replication and suppression of host antiviral silencing response (1, 2) . 43
The host partner of VPg is the eIF4E, an mRNA 5' cap-binding protein. The eIF4E 44
and VPg are the major determinants of resistance versus susceptibility to potyvirus 45 infection; plants are virus-resistant when mutations in eIF4E or in VPg preclude their 46 interaction (3 -6). However, higher plants produce two isoforms of eIF4E and 47 tyrosine 64 to alanine (pVPg5A1) or tyrosine 64 and glycine 54 to alanines 134 (pVPg5A2). These peptides in fusion with GST were expressed and purified (Fig.  135   3C ). The VPg5 mutants were analysed for their interaction with human eIF4E (Fig.  136   3D ). Both VPg5 mutants interact rather weakly with human eIF4E, only slightly better 137 than with GST. Interestingly, rather weak interaction could be observed also for a 138 complete VPg protein (but which was on the same level as that shown in Fig. 2) . 139
Effect of VPg peptides on neoplastic cells in culture. This effect was 140
investigated on HCT116 colon carcinoma cells in culture, transduced with Tat fusions 141 of VPg5 and VPg5A2. Treatment of neoplastic cells with TAT-VPg5 resulted in 142 marked cell death, while TAT-VPgA2 despite low binding to eIF4E appears to act 143 only somewhat less well than Tat-VPg5 (Fig. 4) . Cell death induced by Tat-VPg5 was 144 accompanied by reduction in eIF4E level (Fig.4, BC) . 145 146 Discussion 147 Nuclear eIF4E participates in a variety of important RNA processing events 148 including nucleocytoplasmic transport of specific, growth regulatory mRNAs. Indeed, 149 the availability of eIF4E is believed to be critical for nuclear export and translational 150 activation of capped mRNAs with extensive secondary structures in their 5' 151 untranslated regions (UTRs) (20), many of which code for the labile regulatory 152 proteins essential for cell growth or viability. Various molecular mechanisms of cell 153 growth converge on eIF4E, and it appears that eIF4E is a critical node in RNA 154 regulation influencing nearly every stage of cell cycle progression (16). Thus, eIF4E, 155 besides its direct cytoplasmic role in protein synthesis, seems to have another, 156 nuclear function, whereby by promoting the export of messenger RNA of several 157 proteins involved in cell cycle it plays a key role in regulation of cell growth and 158
survival. 159
Elevated expression of eIF4E leads to oncogenic transformation in tissue culture, 160 cancers in animal models and poor prognosis in some human cancers. Reduction of 161 eIF4E level can reverse the transformed phenotype, which suggests that eIF4E could 162 be exploited as a therapeutic target. A validation of eIF4E as a therapeutic target has 163 been provided by in vivo experiments, in which suppression of eIF4E expression in 164 mice by eIF4E-specific antisense oligonucleotides (ASO) reduced tumor growth in 165 mice (21). Despite reducing the eIF4E levels in mouse liver by 80%, administration 166 of eIF4E-specific ASO did not affect the body weight or the liver enzymes. This 167 suggested that the malignant tumors might be more susceptible to eIF4E inhibition 168 than the normal tissues. Most importantly, a human trial on acute myeloid leukemia 169 patients in whom eIF4E was inactivated with ribavirin, a cap structure mimic (and 170 thus an eIF4E inhibitor) resulted in tumor growth inhibition and cancer remission thatwere correlated with eIF4E reduction and translocation of nuclear eIF4E to the 172 cytoplasm in blasts (15, 22) . Recently, a phase I trial of ribavirin and low-dose 173 cytarabine for the treatment of acute myeloid leukemia with elevated eIF4E has been 174 terminated, showing that the combination was well tolerated, with some patients 175 having a full molecular response with both reduction of eIF4E levels and eIF4E re-176 localization to cytoplasm (23). 177
The eIF4E binding partners such as 4E-BPs, Gemin5, Xenopus Maskin and 178 mammalian neuroguidin, have all been shown to exert translational control (24). 179
These factors usually block the interaction between eIF4E and the scaffold-like 180 eIF4G factor, involved in the formation of the large translation initiation complex 181 eIF4F (25). They all contain the dorsal eIF4E-binding motif YxxxxLØ. Another type 182 of eIF4E effectors, the PML protein and the arenaviral protein Z use their respective 183 RING domains to directly interact with the dorsal surface of eIF4E, thus reducing the 184 affinity of eIF4E for its ligand, 5' cap of mRNA (26, 27). These two proteins shuttle 185 between nucleus and cytoplasm (28), and thus can interact with both nuclear and 186 cytoplasmic eIF4E pools. In addition, a transcription factor, homeodomain protein 187 PRH/HEX that binds nuclear eIF4E inhibits eIF4E function only when its NLS is intact, 188
i.e. it must be nuclear to inhibit eIF4E (29), whereas VPg protein delivered alone 189
shows an exclusively cytoplasmic localization. More importantly, VPg does not 190 contain the eIF4E-binding motif YxxxxLØ or the RING domain, which suggests that 191
VPg interaction with eIF4E occurs at different eIF4E site. Some plants became 192 resistant to potyviruses due to the eIF4E mutations abolishing interaction with VPg. conceivably could be extended to other neoplasms driven by eIF4E overexpression. 218
A partially identified site on PVY VPg served here as a source of five peptides, out of 219 which some interacted better with eIF4E than complete VPg protein. We have chosen2 and 3). In parallel we designed a mutant VPg5A2, which showed rather low-level 222 interaction with eIF4E. These peptides were delivered to neoplastic HCT116 cells in 223 a form of the N-terminal fusions with transducing Tat peptide (36). As use of Tat 224 peptide might introduce several artefacts, we followed the conditions developed for 225 minimizing the nonspecific Tat peptide activity (37). Viability of neoplastic cells was 226 significantly diminished by addition of Tat-VPg5 peptides, in a dose dependent 227 manner, quite strongly with the original VPg5 peptide, somewhat less with VPg5A2 228 peptide. Of note, designing the control -eIF4E-nonreacting -peptide is rather difficult, 229
as there is no structural data identifying the amino acid residues of PVY VPg 230 interacting with eIF4E. 231
It is possible that NLS of VPg (probably starting from 41 Arg) is not functioning when 232 the complete protein (188 amino acid residues) is delivered upon expression in insect 233 cells, as complete VPg brought alone was localized exclusively to cytoplasm (Fig. 1) . 234
However, it is quite plausible to think that NLS in the VPg5 peptide could be functional 235 and VPg5 would go directly to the nucleus, interacting there with the pro-oncogenic 236 nuclear eIF4E. Nevertheless, the eIF4E localization seen after treatment with VPg5 237 (Fig. 4 B,C) shows strong reduction of nuclear eIF4E but nearly complete depletion 238 of factor in the cytoplasm. Further experiments including confocal microscopy would 239 more precisely describe the intracellular effect and localization of VPg5. 240
In conclusion, results obtained with VPg5 peptide show its activity as a novel, 241 efficient inhibitor of eIF4E, leading to death of neoplastic cells, which is accompanied 242 by reduction in eIF4E level. This kind of specific oncogene eIF4E inhibitors should 243 be analysed in eIF4E-driven cancers; it was thought that about 30% of human 244 malignancies show overexpression of eIF4E (38), however, more detailed data
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Materials and methods 253
Materials. T. ni insect cells (Invitrogen) were grown as described by Grzela et al 254
(19). Anti-eIF4E mAb that recognized human and animal eIF4E was from Santa Cruz 255 Biotechnology (USA). Anti-eIF4E recognizing human, mouse and insect eIF4E, was 256 a gift of Nahum Sonenberg (McGill University, Canada). Anti-VPg rabbit polyclonal 257 antibody was prepared in ESD (France), using as antigen PVY hisVPg expressed in 258 baculovirus (19) and was affinity-purified with VPg immobilized on CNBr-activated 259
Sepharose 4B (Amersham Bioscience). Goat anti-GST-HRP antibody was from 260
Rockland Immunochemicals Inc. Molecular weight markers for SDS-PAGE were from 261 Thermo Scientific. Rabbit polyvalent anti-Dd serum was prepared in the laboratory 262 using as antigen a mixture of well-formed and ultrasound-treated Dd. fusion with the GST protein (at the N-terminus of the peptide). To obtain GST-298 VPg5A2, mutagenesis was done using Q5® Site-Directed Mutagenesis Kit (NEB) 299 and a GST-VPg5 in pGEX4T-1 as a template. In VPg5A1 the Gly54 has been 300 changed to Ala, in VPg5A2 both Gly54 and Tyr64 has been changed to Ala. Thethe pVPg5 sequence. The correct sequence of mutants was confirmed by DNA 303
sequencing. 304
VPg5A1 305
F1A AGCAGGAGGTTCATTAACATGGCCGGGTTCTAATAGCTCGAG 306
R1A TGACTTGCCCATACCAACTGTGGTACCTTTACC 307
VPg5A2 308 
GST peptides were expressed in E. coli Rosetta2(DE3)pLyS as follows. 315
Bacteria were grown in the presence of 100 μg/ml of carbenicilillin and 20 μg/ml 316 chloramphenicol, initially at 37°C. Protein production was induced with 400 μM IPTG 317 at OD600 equal 0.6, then the temperature was switched to 30 o C and 4h later the 318 bacteria were harvested. Cell pellet from 250 ml culture was suspended in 10 ml of 319 50 mM Hepes buffer, pH 7.4, containing 300 mM NaCl, 5 mM DTT, 0.5 mM EDTA 320 and supplemented with the protease inhibitor cocktail (Complete, Roche) and 321 lysozyme (LabEmpire) at 1mg/ml. The bacteria were lysed by sonication on ice. The 322 lysates were then centrifuged at 14 000 rpm for 30 min at 4°C and the supernatants 323 were filtered through 0.2 μm filter before applying onto 0.5 ml Glutathione-Sepharose 324 4B column (GE Healthcare). After 4 washes with 10 ml of lysis buffer GST-fusion 325 proteins were eluted with five 1ml portions of 10 mM reduced glutathione in lysis 326
buffer. 327
Human eIF4E was cloned in plasmid pETM30 (EMBL) with 6xhis tag attached 328 at the N-terminus. The protein was expressed in E. coli BL21(DE3) and purified by 329 affinity chromatography on a nickel column (HisTrap HP, GE-Healtcare). Plant eIF4E 330 was prepared in fusion with GST tag attached at the N-terminus in plasmid pGEX4T-331 1 and expressed in E. coli BL21(DE3). The protein was purified on a Glutathione-332 Sepharose 4B column. 333
Interaction of GST-VPg peptides with human eIF4E (ELISA). The 96-well 334
plates (Nunc) were coated with human eIF4E in 0.1 M carbonate buffer, pH 9.6 (100 335 (Fig. 1C) was followed by densitometry. 544 
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